For example, frequent RAS/BRAF mutations impact on the clinical management of CRC, and it is documented that human colon cancers bearing mutated KRAS will not be responding to cetuximab (anti-EGFR monoclonal antibody) treatment. The gene discussed is KRAS; the disease is colorectal carcinoma.